Safety and efficacy of liposomal doxorubicin in a patient treated for metastatic breast cancer
Languages of publication
Breast cancer is the most common malignancy among women in Poland and all over the world. Despite the development of modern therapies, cytostatics still play one of the main roles in treatment of this disease. Classic anthracyclines, besides unquestionable efficacy in this disease, have a disadvantageous toxicity profile. Therefore, until now, there has been a limitation in using these drugs in patients with cardiological conditions and in patients who had previously taken anthracyclines. That was the cause for the development of a less toxic form of drug, which is liposomal doxorubicin – being as effective as classic anthracycline it has reduced cardiotoxicity. This article presents the case of a patient with metastatic breast cancer, in whom, after treatment with classic doxorubicin, liposomal form was administered which caused regression of liver metastases. Moreover, during treatment with liposomal doxorubicin, there has been no evidence of heart impairment.
- 1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
- 2. Ban KG, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am 2014; 23: 409-422.
- 3. [online: http://onkologia.org.pl/nowotwory-piersi-kobiet].
- 4. Clavarezza M, Venturini M. Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer. Oncology 2009; 77(suppl. 1): 14-17.
- 5. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol 2010; 33: 637-645.
- 6. Adamcova M. Lencova-Popelova O, Jirkovsky E et al. Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. Int J Cardiol 2015; 201: 358-367.
- 7. Harris L, Batist G, Belt R. et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25-36.
- 8. O’Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004: 15: 440-449.
- 9. Anton A, Ruiz A, Plazaola A et. al. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 2011; 22: 74-79.
- 10. Yardley DA, Noguchi S, Pritchard KI et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013; 30: 870-884.
- 11. Jassem J, Krzakowski M (ed.). Rak piersi. Praktyczny przewodnik dla lekarzy. Wydanie 2. Via Medica, Gdańsk 2014: 215-216.
- 12. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl. 7): vii11-19.
- 13. Batist G, Remakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin with cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
- 14. Mross K, Niemann B, Massing U et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 2004; 54: 514-524.
Publication order reference